Home » Newsletters » BioWorld Science

BioWorld Science

March 10, 1999

View Archived Issues

Sugen: Q4 and 1998 year-end highlights

Orion: 1998 year-end highlights

Aradigm: Q4 and 1998 year-end highlights

Techniclone to present clinical data on newly designated orphan drug at ASCO

Genelabs presents gene switch application

Merck Frosst presents clinical data on COX-2 inhibitor at Canadian meeting

Genzyme Molecular Oncology initiates clinical trials of combined-antigen melanoma vaccine

Zenapax shows positive results in GVHD trial

Enbrel advances to phase II/III trials for chronic heart failure; phase I results presented at ACC

New Drug Submission for Ditropan accepted for review in Canada

NeuroSearch's agreement with Pharmacia & Upjohn for NS-2710 ends; study results reported

Hyseq conducts preclinical testing on novel anticoagulant products

Anticancer glycosidase inhibitors related to swainsonine

Boehringer Ingelheim discloses novel series active against wild-type and mutant HIV-1 RT

Ziracin: lead compound from a new class of antibiotics in late-stage trials at Schering-Plough

Series from Lilly especially useful for hypercholesterolemia in postmenopausal women

Japanese pharmaceutical companies reveal collaborative research on MDR ligands

ICN launches Senetek's antiaging product

Yamanouchi describes novel anticoagulants

Plant-derived topoisomerase II inhibitors patented by Meiji Milk

Chiron's rFGF-2 featured at ACC meeting

Ultrasound imaging enhanced with AI-700 provides accurate assessment of CV disorders

Subanalyses of abciximab trial results presented at ACC meeting

Fragmin found to reduce heart attack and death at 45 days

ACC highlights: ASSENT 2 study supports improved efficacy of TNK-tPA over t-PA

FDA approves new therapy for type II diabetes

Novogen's phenolic hormone-derived anticancer drug shows potent activity against prostate cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...